Obesity:科学家们在非洲人种基因组中找到了肥胖特异性基因

2017-03-15 生物谷 生物谷

在最近的一项研究中,来自美国NIH,国家人类基因组研究所的研究者们首次分析了非洲人以及非洲裔美国人的基因组序列,发现其中有百分之一的人群携带有患肥胖症的基因在,这一结果能够解释为什么肥胖症总是具有家族性的特征。相关结果发表在最近一期的《obesity》杂志上。


(图片摘自www.medicalxpress.com)

在最近的一项研究中,来自美国NIH,国家人类基因组研究所的研究者们首次分析了非洲人以及非洲裔美国人的基因组序列,发现其中有百分之一的人群携带有患肥胖症的基因在,这一结果能够解释为什么肥胖症总是具有家族性的特征。相关结果发表在最近一期的《obesity》杂志上。

根据这一研究,携带SEMA4D基因突变的人群相比其他人群要重将近六磅。而此前几乎所有的关于肥胖症的研究都集中于欧洲人种,尽管近年来非洲人患肥胖症的风险也在持续升高。

肥胖症是一个全球性的健康问题,容易引发早死以及糖尿病高血压、心脏病以及其它癌症的发病风险。虽然肥胖症大部分情况下是由生活习惯以及风俗等导致的,例如过多的卡路里摄入以及运动不足等等,但遗传因素也同样重要。

在该项研究中,科学家们比较了非洲人种中患肥胖症以及健康人群的基因组相关分析,并从中找到了与肥胖症发病相关的基因。此前的研究主要在欧洲人种中进行,而欧洲人基因组中缺乏SEMA4D基因,因此一直没有找到这一关键的引发肥胖症的遗传因素。

研究者们计划重复他们的实验结果,并且通过细胞系以及模式生物水平的试验证明SEMA4D对于肥胖症发病的影响。此外,他们还计划通过更大规模的DNA测序手段寻找其它可能的肥胖基因。这将最终有助于肥胖症的预防与治疗。

原始出处:

Guanjie Chen,Ayo P. Doumatey,Jie Zhou et.al.Genome-wide analysis identifies an african-specific variant in SEMA4D associated with body mass index Obesity 13 March 2017 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1910491, encodeId=e40d1910491a4, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jun 20 10:02:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899109, encodeId=41b8189910910, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Oct 26 13:02:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461749, encodeId=b0321461e495e, content=<a href='/topic/show?id=92c2132003b' target=_blank style='color:#2F92EE;'>#Obesity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13200, encryptionId=92c2132003b, topicName=Obesity)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45616444603, createdName=lingaifan, createdTime=Fri Mar 17 02:02:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588232, encodeId=2ef815882326e, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Fri Mar 17 02:02:00 CST 2017, time=2017-03-17, status=1, ipAttribution=)]
    2017-06-20 智慧医人
  2. [GetPortalCommentsPageByObjectIdResponse(id=1910491, encodeId=e40d1910491a4, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jun 20 10:02:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899109, encodeId=41b8189910910, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Oct 26 13:02:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461749, encodeId=b0321461e495e, content=<a href='/topic/show?id=92c2132003b' target=_blank style='color:#2F92EE;'>#Obesity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13200, encryptionId=92c2132003b, topicName=Obesity)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45616444603, createdName=lingaifan, createdTime=Fri Mar 17 02:02:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588232, encodeId=2ef815882326e, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Fri Mar 17 02:02:00 CST 2017, time=2017-03-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1910491, encodeId=e40d1910491a4, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jun 20 10:02:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899109, encodeId=41b8189910910, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Oct 26 13:02:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461749, encodeId=b0321461e495e, content=<a href='/topic/show?id=92c2132003b' target=_blank style='color:#2F92EE;'>#Obesity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13200, encryptionId=92c2132003b, topicName=Obesity)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45616444603, createdName=lingaifan, createdTime=Fri Mar 17 02:02:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588232, encodeId=2ef815882326e, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Fri Mar 17 02:02:00 CST 2017, time=2017-03-17, status=1, ipAttribution=)]
    2017-03-17 lingaifan
  4. [GetPortalCommentsPageByObjectIdResponse(id=1910491, encodeId=e40d1910491a4, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Jun 20 10:02:00 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899109, encodeId=41b8189910910, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Oct 26 13:02:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461749, encodeId=b0321461e495e, content=<a href='/topic/show?id=92c2132003b' target=_blank style='color:#2F92EE;'>#Obesity#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13200, encryptionId=92c2132003b, topicName=Obesity)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45616444603, createdName=lingaifan, createdTime=Fri Mar 17 02:02:00 CST 2017, time=2017-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588232, encodeId=2ef815882326e, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Fri Mar 17 02:02:00 CST 2017, time=2017-03-17, status=1, ipAttribution=)]
    2017-03-17 skhzy

相关资讯

BMJ:肥胖是癌症第二大可控危险因素,与11种癌症有关!

BMJ刊文称,肥胖是癌症的第二大可控危险因素,与11种癌症有关

Diabetes Care:非2型糖尿病超重和肥胖患者Canagliflozin和芬特明联合用药效果如何?

由此可见,CANA/PHEN可以显著降低体重,对于非2型糖尿病超重和肥胖患者一般耐受性良好。进一步的研究是必要的,以评估这种联合用药对长期体重管理的潜在价值。

Nature: 抑制肥胖新靶点:骨分泌lipocalcin2蛋白通过黑皮质素(melanocortin)4受体抑制食欲

骨分泌荷尔蒙LCN2能够结合大脑受体MCR4从而抑制食欲减少肥胖

Plos One:还不减肥?肥胖增加晚期慢性肾脏疾病的风险!

目前,尚不确定超重,而不是肥胖,是否与晚期慢性肾脏疾病(CKD)相关;身体质量指数(BMI)和晚期CKD之间关联的大小以及CKD是否在不同类型的人之间不同。近期,一项发表在杂志Plos One上文章对这一问题进行了前瞻性队列研究。研究者们通过使用年龄、性别、吸烟和社会剥夺调整的Cox模型以及通过糖尿病、高血压和心血管疾病史进行的亚组分析评估BMI和CKD 4-5期以及终末期肾病(ESRD)之间的关

JAHA:肥胖会增加心脏手术后风险调整的发病率、死亡率和医疗成本!

较高的BMI与死亡率、重大疾病和医院医疗成本增加有关。因此,在风险评估和资源分配中,BMI应重点考虑。

BMJ open:过度肥胖造成的心理阴影可能会影响身体活动能力

最新一项研究表明,人们如果感觉到自己由于体重过高而受到他人的歧视的话,那么他们的活动能力相比其他群体将会有明显的下降。 这项研究发表在《BMJ Open》杂志上,这是第一项大规模地分析“肥胖歧视”与生理活动之间的关系的研究。研究者们分析了英国长期追踪调查中的50岁以上的5400名志愿者的相关信息。 结果显示:那些感觉到自己因为过于肥胖而受到外